The U.S. Food and Drug Administration and the U.S. Customs and Border Protection (CBP) leaders signed an agreement today to maximize inspection and detection capabilities in order to prevent illegal and harmful products entering the U.S. through the nation’s International Mail Facilities (IMFs) and Ports of Entry that pose a threat to public health. Through this joint effort, each agency will work toward enhancing knowledge-transfer to increase efficiency, reduce duplication of efforts and facilitate mission responsibilities. Collaboration on shared laboratory space, scientific equipment and facilities, along with intellectual, historical and institutional knowledge will optimize the resources at each agency’s disposal.
“Today’s letter of intent demonstrates the FDA’s ongoing work with CBP and our other federal partners, to ensure that FDA-regulated products imported into the U.S. are safe and otherwise comply with federal law,” said FDA Commissioner Scott Gottlieb, M.D. “Thousands of illicit and dangerous products come from overseas each day, such as unapproved fentanyl products, counterfeit prescription drugs or fake over-the-counter products that look legitimate. In recent years, we’ve committed new resources and have been granted new authorities by Congress to target these violative products and stop them before they’re able to enter our country. When bad actors try to circumvent the safety of our supply chains by breaking federal law, we’ll take all appropriate action necessary to ensure these potential risks do not harm the American public.”